Can We Avoid Dose Escalation for Intermediate-Risk Prostate Cancer in the Setting of Short-Course Neoadjuvant Androgen Deprivation?

OncoTargets and Therapy - New Zealand
doi 10.2147/ott.s102327
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Informa UK Limited

Related search

Is Neoadjuvant Androgen Deprivation Therapy Necessary for Patients With Intermediate-Risk Prostate Cancer Treated With Proton Therapy?

International Journal of Radiation Oncology Biology Physics
OncologyRadiologyCancer ResearchRadiationNuclear MedicineImaging
2016English

Risk of the "Androgen Deprivation Syndrome" in Men Receiving Androgen Deprivation for Prostate Cancer

Archives of Internal Medicine
2006English

Benefit of Whole Pelvic Radiotherapy Combined With Neoadjuvant Androgen Deprivation for the High-Risk Prostate Cancer

Journal of Biomedicine and Biotechnology
2009English

High-Dose Radiation Employing External Beam Radiotherapy and High-Dose Rate Brachytherapy With and Without Neoadjuvant Androgen Deprivation for Prostate Cancer Patients With Intermediate- And High-Risk Features

Prostate Cancer and Prostatic Diseases
Cancer ResearchOncologyUrology
2006English

The Need for Androgen Deprivation Therapy in Patients With Intermediate-Risk Prostate Cancer Treated With Dose-Escalated External Beam Radiation Therapy

International Journal of Radiation Oncology Biology Physics
OncologyRadiologyCancer ResearchRadiationNuclear MedicineImaging
2015English

Evaluation of the Effectiveness of Adding Androgen Deprivation to Modern Dose-Escalated Radiotherapy for Men With Favorable Intermediate-Risk Prostate Cancer

Cancer
Cancer ResearchOncology
2016English

Androgen Deprivation Therapy for Prostate Cancer and Risk of Dementia

BJU International
Urology
2019English

Androgen Deprivation Therapy for Prostate Cancer

2017English

Use of Androgen Deprivation Therapy With Radiotherapy for Intermediate- And High-Risk Prostate Cancer Across the United States

JAMA Oncology
Cancer ResearchOncology
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy